Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.
Zhou Q, Yang N, Zhao M, Huang D, Zhao J, Yu Y, Yuan Y, Sun L, Dong X, Zhang T, Chu Q, Li X, Meng X, Wang H, Wang X, Wu D, Hu S, Shan J, Liu L, Sun M, Zhang Z, Zhu H, Huang J, Huang M, Cheng L, Zhang S, Zhou H, Wu YL.
Zhou Q, et al. Among authors: meng x.
Eur J Cancer. 2024 Nov;212:114337. doi: 10.1016/j.ejca.2024.114337. Epub 2024 Sep 26.
Eur J Cancer. 2024.
PMID: 39357276
Clinical Trial.